10x Genomics (TXG) Expected to Announce Earnings on Thursday

Key Points

• 10x Genomics is expected to report Q3 2026 results on November 5, with analysts forecasting a loss of $0.267 per share and revenue of $147.96 million.
• In its previous quarter, the company beat EPS and revenue estimates, but revenue declined 12.7% year over year and the business remained unprofitable. Analysts project full-year and next-year losses of $0.77 and $0.58 per share, respectively.
• Analyst sentiment remains mixed, with a consensus “Hold” rating and a $68 target price versus the stock’s reported $83.62 price; company insiders have sold about $11.8 million in shares over the past 90 days.

10x Genomics (NASDAQ:TXG - Get Free Report) is anticipated to release its Q3 2026 results after the market closes on Thursday, November 5th. Analysts expect 10x Genomics to announce earnings of ($0.2670) per share and revenue of $147.96 million for the quarter. Individuals may review the information on the company's upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Thursday, November 5, 2026 at 4:30 PM ET.

10x Genomics (NASDAQ:TXG - Get Free Report) last released its quarterly earnings results on Thursday, August 6th. The company reported ($0.14) EPS for the quarter, beating analysts' consensus estimates of ($0.24) by $0.10. The firm had revenue of $151.04 million during the quarter, compared to analyst estimates of $146.67 million. 10x Genomics had a negative net margin of 12.18% and a negative return on equity of 9.33%. The business's revenue for the quarter was down 12.7% on a year-over-year basis. During the same period in the previous year, the business earned $0.28 EPS. On average, analysts expect 10x Genomics to post ($0.77) EPS for the current fiscal year and ($0.58) EPS for the next fiscal year.

10x Genomics Stock Performance

10x Genomics stock opened at $83.62 on Thursday. The stock has a market cap of $10.89 billion, a P/E ratio of -141.73 and a beta of 1.99. 10x Genomics has a fifty-two week low of $12.34 and a fifty-two week high of $102.81. The firm's fifty day moving average price is $73.66 and its 200-day moving average price is $40.00.

Analysts Set New Price Targets

TXG has been the subject of several research analyst reports. Piper Sandler lifted their price objective on 10x Genomics from $47.00 to $80.00 and gave the company a "neutral" rating in a research note on Monday, September 28th. Barclays upped their target price on 10x Genomics from $52.00 to $110.00 and gave the stock an "overweight" rating in a research note on Wednesday, October 7th. Stephens cut 10x Genomics from an "overweight" rating to an "equal weight" rating in a report on Friday, October 23rd. Leerink Partners lifted their price target on 10x Genomics from $40.00 to $90.00 and gave the company a "market perform" rating in a research report on Tuesday, September 29th. Finally, Citigroup boosted their price objective on 10x Genomics from $45.00 to $50.00 and gave the stock a "neutral" rating in a report on Friday, August 7th. Five equities research analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, 10x Genomics presently has a consensus rating of "Hold" and a consensus target price of $68.00.

Insider Buying and Selling at 10x Genomics

In other news, CEO Serge Saxonov sold 25,000 shares of the company's stock in a transaction dated Tuesday, September 22nd. The stock was sold at an average price of $81.22, for a total value of $2,030,500.00. Following the completion of the transaction, the chief executive officer directly owned 1,050,249 shares in the company, valued at approximately $85,301,223.78. This represents a 2.33% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Adam Taich sold 46,388 shares of the stock in a transaction dated Wednesday, September 9th. The shares were sold at an average price of $64.57, for a total value of $2,995,273.16. Following the transaction, the chief financial officer owned 316,344 shares in the company, valued at $20,426,332.08. This trade represents a 12.79% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders have sold 179,333 shares of company stock valued at $11,810,070. 8.84% of the stock is currently owned by company insiders.

About 10x Genomics

10x Genomics, Inc is a life sciences technology company that develops tools for analyzing biological systems at the single-cell and spatial levels. Its technologies are designed to help researchers study gene expression, cellular interactions, tissue organization and other biological processes in greater detail than conventional laboratory methods.

The company's product portfolio includes the Chromium platform for single-cell analysis, the Visium platform for spatial transcriptomics, and the Xenium platform for high-resolution in situ analysis of tissue samples.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.